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Abstract
Nipsnap1 (4-nitrophenylphosphatase domain and non-neuronal SNAP25-like
homolog 1) is a novel mitochondrial protein shown to interact with the intracellular
domain of amyloid precursor protein (APP), one of the key biomarkers implicated in
Alzheimer’s disease (AD) pathology. A formerly developed expression strategy for
Nipsnap1 based on the pET-28a expression system showed direct binding of purified
recombinant Nipsnap1 to NAD+ and NADP+. This was further confirmed using Circular
Dichroism (CD) spectroscopy, indicating that NAD+ binding produces a structural
change in Nipsnap1.
To address the low yield of Nipsnap1 protein in the former expression system,
several approaches and conditions were evaluated in this study. A GST-fusion strategy
was developed to stabilize the recombinant protein. GST fusion did not result in
sufficient solubility of Nipsnap1, with the majority of expressed GST-fused Nipsnap1
aggregating in inclusion bodies. Growth curve analysis showed that Nipsnap1 expression
did not cause a bacteriostatic effect. After several experiments to optimize induction,
solubilization and purification of recombinant Nipsnap1, the yield for Nipsnap1 remained
low, but several truncated forms of Nipsnap1 were expressed in higher quantities. Future
strategies of recombinant Nipsnap1 expression and purification may benefit from the use
of a codon-optimized form of Nipsnap1 introduced into expression systems known to aid
in protein solubility and stability.
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I – INTRODUCTION AND BACKGROUND
Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disease and the
most common cause of dementia (Wilson 2012; Barker 2002), a group of symptoms that
begins with deterioration in memory (Reitz 2011), with an eventual decline in language
and cognitive functionality and skills. AD is the 6th leading cause of death in the United
states, currently affecting 5.7 million Americans over the age of 65 (alz.org) and is
projected to grow to 88 million by 2050 (He 2016; US Census Bureau 2014). Current
estimates state that AD and other dementias will cost the US $277 billion, with projected
costs to rise as high as $1.1 trillion by 2050. Early and accurate diagnosis could save up
to $7.9 trillion in medical care and costs (alz.org)
There is currently no definitive test for AD diagnosis. Physicians currently rely on
several tools and assessments to make a differential diagnosis, including cognitive tests,
neurological examinations, brain imaging, and obtaining the medical and family history
of the individual (alz.org)
AD pathology is characterized by the accumulation of two proteins, including an
abnormal form of the tau protein (tau tangles) inside of neurons, and the protein fragment
amyloid-beta (Aβ) outside of neurons. Additional hallmarks of AD pathology include
chronic inflammation, loss of neuronal connections and cell death, and numerous
vascular issues (nia.nih.gov).
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Amyloid precursor protein
Amyloid precursor protein (APP) is a single pass transmembrane protein and is a
member of the APP family of proteins, including amyloid precursor-like protein 1
(APLP1) and amyloid precursor-like protein 2 (APLP2) (Zhang 2011), which play
essential but redundant roles during development (Heber 2000). The APP family of
proteins are expressed in the developing and mature brain at the somal cell surface along
growing axons and at the axonal growth cone (Selkoe 2002). APP is primarily processed
within the Aβ sequence by α-secretase, releasing a soluble fragment known as APPS-α.
This fragment has been shown to regulate APP function in neurite outgrowth through
competition for the binding of integrin β with APP (Younge-Pearse 2008). Secreted
forms of APP formed via α-secretase processing have been shown to have neurotrophic
and neuroprotective properties via stabilization of the intraneuronal concentration of
calcium (Mattson 1993).
APP can additionally undergo processing by β-secretase and γ-secretase. When
aberrant processing of APP occurs by β-secretase, 40-42 amino acid (AA) long fragments
of Aβ aggregate to form Aβ plaques. Mutations in APP that result in an increase of this
aberrant processing is associated with some early onset forms of AD (Murrell 1991). Aβ
plaques are neurotoxic through an interaction with Aβ-binding alcohol dehydrogenases
(ABAD) and cyclophilin D (CypD), resulting in large-scale neuronal death over time. Aβ
can induce apoptosis in cultured neurons directly by lipid peroxidation (Loo 1993). The
remaining 83 AA long fragment of APP untouched after β-secretase cleavage can further
be processed by γ-secretase, resulting in further cleavage and generation of the amyloid
precursor protein intracellular domain (AICD). The AICD has been shown to induce
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significant changes in gene expression and neuron-specific apoptosis, suggesting APP
may be involved in signaling closely linked to AD pathology, and suggests a correlation
in gene expression in neuron specificity of AICD-induced cell death (Nagase 2014;
Ohkawara 2011). The AICD has furthermore been shown to induce neurotoxicity in rat
primary cortical neurons by upregulating glycogen synthase kinase 3β (GSK-3β)
expression and increasing tau phosphorylation (Kim 2003), one of the hallmarks of AD
pathology that is highly correlated with dementia (Wang 2013).

Nipsnap1 is an APP-interacting protein
Previous work in our laboratory showed that the AICD interacts with the novel
protein 4-Nitrophenylphosphatase Domain and Non-Neuronal SNAP25-Like Homolog 1
(Nipsnap1) using a functional proteomics approach (Tummala 2010). A synthetic peptide
corresponding to APLP1 C-terminus or a randomized control peptide were cross-linked
to an agarose resin and used for affinity chromatography. Mouse brain lysate was passed
through the columns, and bound proteins were further separated by sodium
dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE), and visualized by silver
staining, where a ~30 kDa protein was identified. The protein was trypsin-digested and
subsequently sequenced using mass spectrometry. The molecular masses of 11 derived
peptides were determined by matrix-assisted laser desorption ⁄ ionization time-of-ﬂight
mass spectrometry and used to search the non-redundant protein databases at NCBI. The
protein was identiﬁed as Nipsnap1 (NM_008698) with approximately 40% sequence
coverage. The protein was additionally found to be targeted to mitochondria via an N-
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terminal mitochondrial targeting sequence and shown to interact with mitochondrial
chaperone translocase of the outer membrane 22 (TOM22).

Evolutionary conservation of the Nipsnap1 C-terminal domain
Nipsnap1 belongs to a family of four genes (Table 1): Nipsnap1, Nipsnap2 (also
known as GBAS), Nipsnap3 (also known as Nipsnap3B) and Nipsnap4 (also known as
Nipsnap3A and TassC). Mitoprot analysis (Claros 1995) predicts that all four family
members of the Nipsnap family have mitochondrial targeting sequences. Among the four
Nipsnap proteins, Nipsnap1 and 2 share high sequence identity (75% identity of 245
residues overlap). An alignment of the four Nipsnap proteins in mouse is shown in Figure
1.
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Figure 1. Sequence alignment of the four Nipsnap homologues in mouse. Alignment was
generated using Clustal Omega 1.2.4 (Goujon 2010, Sievers 2011). Fully (*), strongly (:),
and weakly (.) conserved residues are noted. Higher conservation of residues can be seen
towards the C-terminus of the protein.
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Table 1. Overview of the four Nipsnap homologues. Alternative names found in literature, human
chromosomal locations (Casper 2018), tissues of highest expression, and the number of total amino
acids in each homolog are shown.
Gene

Alternative Names

Nipsnap1
Nipsnap2

GBAS

Nipsnap3A

Nipsnap4, TassC

Nipsnap3B

Nipsnap3

Location (hg38)
chr22:29,554,80829,581,337
chr7:55,964,581-56,000,181
chr9:104,747,688104,760,122
chr9:104,764,170104,774,010

Highest Expression

Amino
Acids

Liver, brain

284

Brain, muscle

286

Testis, fetal brain

247

Skeletal muscle, testis

247

The structure and functions of Nipsnap1 are unknown
Nipsnap1 is an evolutionarily conserved protein found in a wide range of species
including plants, C. elegans, zebrafish, mouse and human, with high sequence
conservation stretching back to bacteria (Figure 2). However, the name Nipsnap1 (4
nitrophenyl phosphatase and non-neuronal SNAP25 like protein homolog1) is a
misnomer; the protein has no known phosphatase or SNAP25 like domain or function.
The protein is called Nipsnap1 due to it being found in the C. elegans operon present
between the genes similar to yeast nitrophenyl phosphatase (cosmid K02D10 acc.
L14710) (Sulston 1992) and mouse synaptosomal associated protein 29 (SNAP29)
(Figure 3).
Human Nipsnap1 was characterized and found to be localized on chromosome
22q12 (Seroussi 1998). It was found that the gene had 10 exons which coded for a 284
amino acid protein and contained an unusual TATA-less GC-rich promoter sequence.
Although there is limited knowledge pertaining to the structure and function of Nipsnap1,
the gene exhibits widespread tissue expression in human and mouse, with highest levels
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of expression in the liver and kidneys. Moderate expression is seen across nervous tissue,
predominantly in the frontal cortex (Figure 4).

Figure 2. Sequence alignment of Nipsnap1 proteins from Rhizobium radiobacter,
zebrafish, mouse, and human. Alignment was generated using Clustal Omega 1.2.4
(Goujon 2010, Sievers 2011). Fully (*), strongly (:), and weakly (.) conserved residues
are noted. High conservation of residues spanning through evolutionary divergent species
can be seen towards the C-terminus of the protein as highlighted.
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Figure 3. Nipsnap 1 (K02D10.1) as shown in the University of California Santa Cruz (UCSC) Genome Browser on C. elegans
Feb. 2013 (WBcel235/ce11) Assembly (Howe 2016). The mammalian protein is called Nipsnap1 due to it having strong
sequence similarity to a hypothetical protein found in the C. elegans operon (Sulston 1992) present between the genes similar
to yeast nitrophenyl phosphatase (K02D10.1) and mouse synaptosomal associated protein 29 (SNAP29) on chromosome III.
Relevant genes are noted with arrows.
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There is no mammalian Nipsnap crystal structure available to date. However,
crystal structures for Nipsnap proteins of certain agrobacterium such as Agrobacterium
tumefacience do exist (Figure 5) (unpublished data from PDB database, Joint Center for
Structural Genomics 2005). Structures are available for hypothetical protein atu4242
(1VQS) and atu5224 (1VQY) from Agrobacterium tumefaciens at 1.50 Å and 2.40 Å
resolutions, respectively. Another crystal structure is available for atu4242 (2AP6). The
data were deposited by the Joint Center for Structural Genomics and Northeast Structural
Genomics Consortium. In rat liver mitochondria, Nipsnap1 (apparent mass 29 kDa) was
identified as a complex with an apparent mass of 100−120 kDa, suggesting a
homotrimeric assembly and/or association with another unidentified protein
(Reifschneider 2006).

9

Figure 4. Human Nipsnap1 gene expression across tissues from Genotype-Tissue Expression project (GTEx) release V6
(GTEx Consortium, 2013). Highest Nipsnap1 expression is found in the liver, kidney, adrenal gland, and Epstein-Barr virustransformed (EBV, herpes virus 4) lymphocytes. Moderate expression is seen across nervous tissue, predominantly in the
frontal cortex.
10

Figure 5. Crystal structure of a NIPSNAP protein from Agrobacterium tumefacience. (A) Biological Assembly Image for the
crystal structure of a NIPSNAP family protein (atu4242) from Agrobacterium tumefaciens str. c58, 1VQS, at 1.50 Å
resolution. (B) Biological assembly image for 1VQY, crystal structure of a NIPSNAP family protein (atu5224) from
Agrobacterium tumefaciens str. c58 at 2.40 Å resolution. (A) and (B) were submitted by The Joint Center for Structural
Genomics. (C) Biological assembly image for 2AP6, X-ray crystal structure of protein Atu4242 from Agrobacterium
tumefaciens. The data was submitted by Benach J et al., Northeast Structural Genomics Consortium. Data was acquired from
the RCSB Protein Data Bank (Berman 2000), and the images generated by PISA and PQS (Goshal, unpublished).
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Insight into Nipsnap1 function
Although little is known regarding Nipsnap1 function; protein distribution,
screening/association studies and Nipsnap1 involvement in disease models have given
some insights into its potential roles in vivo.
Gene expression analysis of heterozygous X-box binding protein 1 (XBP1)
knockout mice showed that several genes on 11qA1 have altered expression, including
strong upregulation of Nipsnap1 (Takata 2010). Nipsnap1 has been shown to inhibit
transient receptor potential vanilloid channels 5 and 6 (TRPV5/6), Ca2+ ion channels
expressed in mouse intestinal tissues (Schoeber 2008). Further evidence suggests
Nipsnap1 has vital roles in the brain; an increase in Nipsnap1 expression was found in the
postsynaptic density fraction (PSD) of mouse forebrains in a chemically induced epilepsy
model (Satoh 2002), and changes in the PSD are believed to be vital in regulation of
synaptic plasticity and important in learning and memory (Goelet 1986; Ehlers 2003).
Nipsnap1 was found to be expressed exclusively in neurons in mouse central
nervous system (CNS), including pyramidal neurons in the cerebral cortex, Purkinje
neurons in the cerebellum, and motor neurons in the spinal cord (Nautiyal 2010). Further
work has determined Nipsnap1 can bind directly to the E2 subunit of pyruvate
dehydrogenase in the branched chain amino acid (BCAA) metabolon (Islam 2010),
suggesting a possible role for Nipsnap1in BCAA metabolism in mitochondria. Nipsnap1
has also been found to interact with the neuropeptide nocistatin (NST) and may play a
role in pain transmission (Okuda-Ashitaka 2012) via mediating NST in inhibition of
nociception/orphanin FQ (N/OFQ)-evoked tactile pain allodynia (Okuda-Ashitaka 2015).
Nociceptive behavioral response increased in phase II of the formalin test (Hunskaar
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1987) in Nipsnap1 deficient mice, suggesting that alteration of Nipsnap1 expression
contributes to the pathogenesis of inflammatory pain (Okamoto 2016). Our group has
shown that Nipsnap1 contains a mitochondrial targeting sequence at its N-terminus, and
an interaction in its C-terminus with the C-terminal region of amyloid precursor protein
(APP), suggesting that Nipsnap1 may regulate mitochondrial function in neurons
(Tummala 2010). To investigate the function of Nipsnap1, our group generated a knockout (KO) mouse model. We showed that targeted deletion of Nipsnap1 resulted in
significant changes in the levels of many intermediate metabolites, not just those
associated with BCAA metabolism (Ghoshal 2014).
Metabolomic profiling of brain and liver tissues from Nipsnap1 deficient mice
revealed significant differences in nucleotide intermediates and NAD+ precursors
(Ghoshal 2014). Two structure-based virtual ligand screening tools, I-TASSER (Iterative
Threading ASSEmbly Refinement) (Zhang 2008; Roy 2010; Yang 2015) and
FINDSITEcomb (Zhou 2013), were used to investigate potential functional roles of
Nipsnap1. As the structure of Nipsnap1 has not been determined experimentally, a
homology model was developed (Figures 6-8) from existing bacterial NIPSNAP crystal
structures and used in screening. I-TASSER uses a hierarchical approach to predict
protein structure and function, by identifying PDB templates using a multiple threading
approach. Findsite performs ligand screening based on binding site conservation across
evolutionary distant proteins identified by threading.
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Figure 6. Alignment of the structure model generated by FINDSITEcomb of the Cterminal fragment of Nipsnap1 to experimental NIPSNAP domain structures (PDB codes
1VQS and 1VQY, shown in grey) (Joint Center for Structural Genomics 2005). The
model of this fragment contains features of the NIPSNAP sequence domain previously
defined by Seroussi et al. (Seroussi 1998)(Pfam ID PF07978) (Eberhardt 2016), including
two α-helical regions from residues 195-215 (red) and 240-266 (yellow) and four βstrands involving residues 184-192 (purple), 218-222 (blue), 230-237 (teal), and 268-274
(green) (Ziebarth unpublished).
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Figure 7. Comparison of Nipsnap1 structural models generated by I-TASSER and
FINDSITEcomb. The I-TASSER model is shown in gray, while fragments 1, 2, and 3 of
the FINDSITEcomb model are shown in blue, purple, and red, respectively. The image
was created by superimposing the the FINDSITEcomb fragments to its corresponding
sequence in the I-TASSER model (Ziebarth unpublished).

Figure 8. Sequence alignment of the NIPSNAP domain containing fragments of
Nipsnap1 (NSP1_I and NPS1_C) with sequences of Nipsnap proteins with experimental
structures (1VQS and 1VQY). Residues from the N-terminal end of the Nipsnap1
fragments NSP1_I and NSP1_C which did not align to the NIPSNAP domain were
removed for clarity (Ziebarth unpublished).
15

Virtual ligand screening of Nipsnap1 identified NADH and NADPH as ligands
that may bind to the NIPSNAP domain. FINDSITEcomb ranked NADH and NADPH as
the two ligands most likely to bind out of a database of over 60,000 compounds. NADH
was also in the top ~1% (734 out of 60,000) for binding to the entire Nipsnap1 protein.
Systems genetics analysis of hippocampal tissue across a panel of recombinant inbred
mouse strains revealed that Nipsnap1 expression tightly correlates with several
dehydrogenases in addition to the previously reported PDH/BCKA dehydrogenases,
including malate dehydrogenase, isocitrate dehydrogenase, and several NADH-Q
reductase subunits.

Significance
Amyloid precursor protein (APP) is a type 1 transmembrane protein (Hynes 1990) whose
mutant forms have been linked to Alzheimer’s disease (AD) (Citron 1992; Murrell 1991).
These mutations result in abnormal cleavage of APP and release of the APP intracellular
domain (AICD) and amyloid beta (Aβ) peptide. Accumulating evidence suggests this
cleavage results in some of the pathological features that are characteristic of AD (Muller
2008; Pimplikar 2010). The precise mechanism by which AICD is involved in normal
and pathologic functions is unknown. An interaction has been described between a
conserved region of AICD and the novel mitochondrial protein Nipsnap1 (Tummala
2010).
Taken together, these data suggest that Nipsnap1 may play an important role in
mitochondrial function via regulation of NAD+/NADH levels. To test this hypothesis,
enzymatic assays on brain tissues of Nipsnap1 deficient mice were performed, and it was
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found that the NAD+/NADH ratio was significantly lower in Nipsnap1 deficient mice
(Figure 9). These data have led to our central hypothesis that Nipsnap1 is an NAD+
binding protein that interacts with and regulates multiple dehydrogenase complexes in the
mitochondria and that AICD, through a direct interaction with Nipsnap1, affects
dehydrogenase activity and neuronal NAD+/NADH levels.

Figure 9. Reduction in NAD/NADH ratio in Nipsnap1 deficient mice. Lysates were
prepared from post-natal day 1 cortex of Nipsnap1 (n=4) and WT (n=4) animals. NAD+
and NADH levels were measured enzymatically using spectrophotometric assay
EnzyChromTM NAD+/NADH assay kit (E2ND-100, BioAssay Systems, CA) according
to manufacturer’s protocol. We found that Nipsnap1 deficiency resulted in lower NAD+
and higher NADH concentrations in the brain. Importantly, the NAD/NADH ratio was
significantly (p<0.000193, student’s t-test, n=4) lower in Nipsnap1 KD brains (Qiao
unpublished).
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Figure 10. Biochemical pull-down using NAD(P). Experiments displayed direct binding
of purified recombinant Nipsnap1 protein to NAD+ and NADP+ immobilized sepharose
beads (Qiao unpublished).

To test if Nipsnap1 binds to NAD+ and NADP+ directly, it is necessary to
generate large amounts of recombinant Nipsnap1 protein. Previous work focused on
expressing His-Tagged recombinant protein using a pET-28a plasmid containing an E.
coli optimized form of the mouse Nipsnap1 gene, minus the mitochondrial targeting
18

sequence (Gacasan unpublished). This expression system was used to perform
preliminary biochemical binding assays, where purified recombinant Nipsnap1 was
incubated with NAD+ or NADP+ immobilized on sepharose beads. Nipsnap1 was shown
to bind to both NAD+ and NADP+ in a concentration dependent manner (Figure 10),
with a slightly higher affinity for NAD+ than NADP+. The Nipsnap1-NAD+ interaction
was further confirmed using circular dichroism (CD) spectroscopy (see results section,
Figure 17), indicating Nipsnap1 undergoes a structural change in the presence of NAD+.

Project Goals
To carefully analyze the NAD binding characteristics of Nipsnap1, larger
quantities of purified recombinant Nipsnap1 were required. In this study, several
approaches and experimental conditions were tested to optimize Nipsnap1 yield. The
pET-28a expression system had failed to give desired levels of Nipsnap1 protein after
optimization of the protocol. With the aim of increasing expression, three new Nipsnap1
constructs were developed based on the glutathione S-transferase (GST) fusion protein
strategy. The expression, solubilization, and purification methods using the above
constructs were then optimized in attempts to maximize the yield of soluble protein for
additional biochemical characterization.
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II – METHODS
Initial expression, purification, and analysis of Nipsnap1 using pET-28a system
Expression of Nipsnap1-pET-28a Construct
Escherichia coli BL21 (DE3) cells (EMD Millipore) were transformed using
pET-28a plasmid containing Nipsnap1. Cells were grown in Luria-Bertani (LB) media
containing kanamycin (30 mg/mL; Acros) at 37°C, with vigorous shaking. Nipsnap1
gene expression was induced using 0.1 mM isopropyl β-D-1-thiogalactopyranoside
(IPTG) (Fisher) once an OD600 = 0.6 was reached, and cultures were grown for 6 hours
post-induction, again at 37°C. Cells were harvested by centrifugation (Sorvall RC-5B
Refrigerated Superspeed Centrifuge) at 6,000xg for 10 min at 4°C, and the resultant
pellets stored at -80°C.
Cell lysis
Cell pellets (1 L) were resuspended in 40 mL buffer A (20 mM NaPO4, 0.5 M
NaCl. and 40 mM imidazole, pH 7.4; Fisher Scientific) containing lysozyme (0.2
mg/mL), benzonase nuclease (1000 units) and a protease-inhibitor cocktail, all from
Sigma-Aldrich. The cell suspension was sonicated, on ice, at 50% power with pulsing
for 5 min using a Biologics, Inc. Ultra Sonic Homogenizer Model 150 VT, then placed on
a rocker for 30 min at room temperature. The resultant lysate was centrifuged at 8,000xg
for 20 min using an AccuSpin 4000 table-top centrifuge. The supernatant, the soluble
cellular fraction, was collected and sterile-filtered using a 0.22 μM filter (EMD
Millipore).
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Purification of Nipsnap1-His recombinant protein
The His-tagged Nipsnap1 protein was purified using Ni-Affinity chromatography.
Supernatant was cycled onto a 1 mL Ni sepharose HisTrap HP column (GE Health
Sciences) for 1-2 hours at 4°C, using a peristaltic pump, to ensure maximum protein
binding. The column was then washed with buffer A for 20 min, to remove any
nonspecifically bound protein, and the bound protein eluted with buffer B (20mM
Na3PO4, 0.5M NaCl, and 500mM imidazole, pH 7.4). Purity was evaluated using
Coomassie staining and Nipsnap1 presence was validated by immunoblot analysis
(Figures A1 and A2).
Circular dichroism spectroscopy
Purified His-tagged Nipsnap1 was analyzed via circular dichroism (CD)
spectroscopy, using an AVIV Circular Dichroism Spectrometer Model 410SF. For initial
runs, 750 uL 7.39 uM Nipsnap1 was diluted with 250 uL 1XTBS (50 mM Tris, 150 mM
NaCl, pH 7.6) and near-UV wavelengths (350-250 nm) were scanned. Additional nearUV scans were performed using 750 uL 1XTBS mixed with 250 uL 0.02 M NAD+, and
750 uL 7.39 uM Nipsnap1 mixed with 250 uL 0.02 M NAD+.
Nipsnap1 expression and optimization using pGEX-4T1 vector
An overview of the expression system and purification strategy is shown in Figure
11 and explained in detail in sections below.
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Figure 11. Diagram showing approach to developing a recombinant Nipsnap1
purification system using the pGEX plasmid. The Nipsnap1 gene was cloned into
pGEX4T-1, its protein expression optimized, and large-scale cultures generated. Cells
were lysed via sonication, and supernatants, were used in protein purification. Protein
verification was performed using Coomassie staining and immunoblot analysis.
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Nipsnap1-pGEX-4T1 expression construct
Mouse Nipsnap1 coding sequence (NCBI Gene ID: 18082) was cloned in-frame
to GST using the pGEX-4T1 plasmid (Sigma). A plasmid map of the pGEX-4T1 plasmid
is shown in Figure 12. The pGEX-4T bacterial expression vector (GE Healthcare Life
Sciences) contains the GST gene in its multiple cloning site. The wild type mouse
Nipsnap1 gene minus the mitochondrial signal sequence was sub-cloned into pGEX-4T-1
using the EcoRI and NotI restriction sites found in the plasmid multiple cloning site.
Custom oligonucleotides were purchased from Integrated DNA Technologies. Primers
shown in table 2 were used to introduce the respective restriction sites to the ends of the
wild type Nipsnap1 gene by PCR using Q5 High-Fidelity DNA polymerase (New
England Biolabs).
Table 2. Primers used to introduce Nipsnap1 into pGEX-4T1. Red, blue, and green
nucleotides correspond to start/stop codons, restriction sites, and additional nucleotides to
bring primer GC content and melting temperature (Tm), respectively, into more optimal
ranges for use in PCR.

Three plasmids were designed, each resulting in a different final form of the
protein, (Full length: Nipsnap1-FL, N-terminal fragment: Nipsnap1-NTF, C-terminal
fragment: Nipsnap1-CTF, see Figure 13). This was done to localize any interactions
Nipsnap1 has to specific parts of the protein. Due to the high evolutionary conservation
of the NIPSNAP protein family C-terminus, we hypothesized any conserved functions
would be localized to this region.
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Figure 12. A) Plasmid map of the pGEX-4T1 plasmid (addgene). Relevant functional
sites utilized in our expression system are denoted by an *. Nipsnap1 was introduced into
the GST variant site controlled by the tac_promoter using the forward primer EcoRI
High-Fidelity (HF) (NEB) and reverse primer NotI HF (NEB) using Platinum Taq DNA
Polymerase (Invitrogen) and T4 DNA Ligase (NEB). B) Primary sequence displaying the
thrombin cleavage and restriction sites.
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Our lab previously generated a Nipsnap1 antibody that recognizes the epitope
NKLKNNKEYLEFRKER; Nipsnap1 constructs were designed keeping this region of the
protein in mind (Figure 13). Due to the epitope being localized in roughly the middle of
the protein, we adjusted the sizes of each truncated construct relative to their original
pET-28a forms to allow for more convenient and precise immunoblot analysis. The
nucleotide sizes and predicted molecular weight of the expressed protein for each of the
Nipsnap1 forms are found in Table 3.

Figure 13. Design map for the three Nipsnap1 constructs developed. FL Nipsnap1 has a
predicted AA length of 262 residues. Our generated antibody recognizes the epitope
shown corresponding to AA140-156. The N-terminus of the protein has been defined as
AA 1-140 shown in blue, with the NTF protein including the entire N-terminus, epitope,
and a slight portion of the C-terminus. The C-terminus is shown in green, with the CTF
protein including the entire C-terminus, epitope, and a slight portion of the N-terminus.
Slight hangover of the other termini is purposely designed in order to ensure epitope
recognition.
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Table 3. Summary of predicted sizes for Nipsnap1 cDNA and protein. Initial protein
exists as a GST-Nipsnap1 fusion protein. Nipsnap1 is cleaved from the 27 kDa GST
during purification.
Form
FL Nipsnap1
NTF Nipsnap1
CTF Nipsnap1

Expected cDNA size
(bp)
813
447
483

Fusion protein size
(kDa)
57
43
45

Cleaved protein size
(kDa)
30
16
18

Figure 14. A) Nipsnap1 cDNAs generated via PCR amplification. All three cDNAs
appear at the correct approximate size. B) Diagram of amplification strategy.
Both the pGEX-4T1 plasmid (not shown) and Nipsnap1 cDNA (Figure 14) were
digested using EcoRI and NotI restriction enzymes, ligated together, and the ligation
products used to transform E. coli DH5α cells (Invitrogen). DNA sequences for all three
constructs were verified through the Molecular Resource Center, University of Tennessee
Health Science Center, Memphis, TN.
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Bacterial culture and growth curve preparation
The verified Nipsnap1-FL pGEX-4T-1 plasmid or empty vector control was used
to transform E. coli BL21(DE3)pLysS Competent Cells (Promega). Cells were grown in
Luria-Bertani (LB) media containing ampicillin at 37°C, with vigorous shaking. Once an
OD600=0.6 was reached, cultures were split into four 10 mL cultures and supplemented
with 0.1 mM IPTG and/or NAD+ as shown in Figure 15. OD readings were measured
hourly for six hours for all four conditions.

Figure 15. Schematic of bacterial growth curve experimentation. BL21(DE3)pLysS
Competent Cells were transformed with either FL Nipsnap1 pGEX-4T1 or empty pGEX4T1 control. Ten mL overnight culture was diluted to 50 mL and grown until OD600 =
0.6, and then separated into four 10 mL fractions. Fractions were either supplemented
with NAD+ and/or IPTG (0.1 mM) or nothing, as shown in the conditions numbered
above.

27

Initial pGEX-4T1 Nipsnap1 expression and purification
Nipsnap1 expression using pGEX-4T system
The verified Nipsnap1 pGEX-4T-1 plasmids were used to transform E. coli BL21
(DE3) cells (EMD Millipore). Cells were grown in LB media containing 50 ug/mL
ampicillin at 37°C, with vigorous shaking. Nipsnap1 gene expression was induced using
0.1 mM IPTG (Fisher) once an OD600=0.6 was reached, and cultures grown for 6 hours
post-induction, again at 37°C. Cells were harvested by centrifugation (Sorvall RC-5B
Refrigerated Superspeed Centrifuge) at 6,000xg for 10min at 4°C, and the resultant
pellets stored at -80°C.
Bacterial lysis
The cell pellet was resuspended in binding buffer (PBS: 140 mM NaCl, 2.7 mM KCl, 10
mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) containing benzonase nuclease (1000 units) and
protease-inhibitor cocktail. The cell suspension was sonicated, on ice, at 50% power with
pulsing for 5 min using Biologics, Inc. Ultra Sonic Homogenizer Model 150 VT. The
resultant lysate was centrifuged at 16,000xg for 90 minutes at 4°C. The supernatant, the
soluble cellular fraction, was collected and sterile-filtered using a 0.22 μM filter (EMD
Millipore).
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Table 4. Buffers used in GST-based protein purification.

A glutathione-s-transferase (GST) fusion system was utilized for affinity
purification (GE Healthcare Life Sciences). Buffers used during purification are detailed
in Table 4, and a complete workflow of the purification strategy is shown in Figure 16.
Purification of GST-bound Nipsnap1 was performed using GSTrap FF and
HighTrapBenzamidine columns from GE Healthcare Life Sciences. Clarified lysate from
bacteria expressing GST-fused Nipsnap1 was cycled onto the GSTrap FF column for 90
min at 4°C. The GSTrap FF was washed with 5 volumes PBS, then 1 mL of PBS
containing 1 U/ul thrombin was introduced into the column, then incubated for 4 h at
room temperature. The GSTrap FF column was then connected to a HiTrap Benzamidine
FF column, and Nipsnap1 was eluted from the column using buffer B1. Columns were
disconnected, GST was washed from the GSTrap FF column with buffer A2, and
thrombin off the HiTrap column using buffer B2.
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Figure 16. Workflow of GST purification strategy (GE Healthcare Life Sciences). Lysate
is loaded on-column and washed with 5 column volumes PBS to remove nonspecifically
bound proteins. Thrombin suspended in PBS is loaded on-column and allowed to
incubate at room temperature to cleave the fusion protein from bound GST. Following
incubation, the GSTrap FF is connected to a HiTrap benzamidine column. Buffer B1 is
eluted through the columns, resulting in thrombin removal from the sample by binding
the HiTrap Benzamidine FF column, and elution of cleaved Nipsnap1 out of the columns.
Sample purification was validated by Coomassie staining to visualize protein
purity and estimate which fractions contained Nipsnap1 after purification. Western blot
analysis was subsequently performed to verify Nipsnap1 presence in eluted fractions
(Figure 19).
Optimization of Nipsnap1 induction
Nipsnap1 induction was optimized by altering several conditions and observing
which gave the highest levels of induced Nipsnap1 protein. Conditions altered include
post-induction incubation time, temperatures used in post-induction incubations, media
composition, and IPTG concentrations given for protein induction.
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Post-induction time at 37 °C
Cultures (10 mL, LB media) transformed with pGEX-4T1 control or Nipsnap1
(Nipsnap1-FL, Nipsnap1-NTF, or Nipsnap1-CTF) were incubated overnight at 37 °C.
Cultures were diluted to 50 mL the following day and grown to an OD600 of 0.6 and
induced using 0.1 mM IPTG. Aliquots (1 mL) were taken immediately before induction
and 3 or 6 h after induction. Coomassie staining was used to visualize total protein for all
constructs (Figure 20).
Post-induction time at 18 °C
Bacterial culture temperature post-induction was lowered in order to reduce the
likelihood of shuttling of expressed protein into inclusion bodies (Figure 21). Cultures
(10 mL, LB media) transformed with pGEX-4T1 control or Nipsnap1-NTF were
incubated overnight at 30 °C. Cultures were diluted to 50 mL the following day and
grown to an OD600 of 0.6 and induced using either 0.1 mM, 0.01 mM, or 0.001 mM
IPTG. Post-induction, the temperature was then dropped from 37 °C to 18 °C, and growth
was monitored at 6, 12, and 18 h to choose a suitable endpoint if there were noticeable
differences in protein expression (Figure 21).
Comparison of post-induction temperatures
To determine if the 18 °C induction-based protocol gives better Nipsnap1 yield
than the original 37 °C induction-based protocol, lysates and supernatants were generated
according to both protocols (Table 5) and evaluated after sonication using the new
sonication conditions. Protein yield was determined by Coomassie (Figure 22) staining
and Western blot analysis (Figure 23).
31

Table 5. Summary of conditions used in comparison of 18 °C and
37 °C induction.

IPTG concentration effects
Cultures (10 mL, LB media) transformed with pGEX-4T1 control or Nipsnap1NTF were incubated overnight at 30 °C. Cultures were diluted to 50 mL the following
day and grown to an OD600 of 0.6 and induced using either 0.1 mM, 0.01 mM, or 0.001
mM IPTG. Cultures were incubated at 18 °C, and growth monitored at 6, 12, and 18 h.
Samples were lysed according to initial protocol (Table 5) and lysates and their resulting
soluble fractions were visualized by Coomassie staining. (Figure 21)
Optimization of Nipsnap1 solubilization
Optimization of Nipsnap1 solubilization was achieved by altering sonication
procedures and lysis conditions (NP40 or lysozyme).
NP40 and lysozyme mediated solubilization
Cultures (10 mL, LB media) transformed with pGEX-4T1 control or Nipsnap1NTF were incubated overnight at 37 °C. Cultures were diluted to 50 mL the following
day and grown to an OD600 of 0.6 and induced using 0.1 mM IPTG and incubated for 3 h.
Bacteria were pelleted at 8000 RPM for 20 min, and resuspended in either PBS, PBS
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supplemented with 1% NP40, lysozyme, or both. Samples were incubated on ice for 20
min, then lysed via an initial sonication method (Table 6) and 1 mL aliquots of lysate
taken. Cell lysates were cleared, and soluble fractions collected as described above. The
resulting pellets were resuspended in PBS/1% NP-40 and sonicated again for 3 minutes,
aliquots of the suspension collected, then again centrifuged and supernatant collected.
Coomassie staining was used to visualize all collected samples (Figure 25).
Optimization of sonication procedure
Overnight bacterial stocks (10 mL) containing empty pET-28a, pET CTFNipsnap1, empty pGEX, or pGEX CTF-Nipsnap1 were incubated overnight at 30 °C.
Samples were diluted to 50 mL LB/1% glucose, and grown at 37 °C until OD600 = 0.6,
then induced with IPTG and allowed to incubate at 18 °C for 6 h. Bacteria were pelleted
at 8000 RPM for 20 min, and then lysed using a new sonication protocol (20% power, 1:1
on/off 50% pulsing, x3 cycles; wait 5 min, repeat cycle 2x – a total of 3 x 30 sec cycles).
Samples were visualized by Coomassie staining (not shown) and Western blot analysis
(Figure 24). A comparison of the initial and final sample protocols is shown in table 6.
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Table 6. Comparison of initial and final solubilization protocols.

Optimization of Nipsnap1 elution
Optimization of Nipsnap1 purification was achieved by increasing thrombin incubation
time to facilitate an increase in Nipsnap1 cleavage from GST. A 50 mL bacterial culture
(CTF-Nipsnap1, empty GST) was centrifuged at 14,000 RPM for 20 min. Resulting
pellets were resuspended in 20 mL PBS/PIC and sonicated on ice for 5 min with pulsing
at 50% power twice. The sample was centrifuged for 90 min max speed, and the
supernatant loaded on GSTrap FF 1mL using a peristaltic pump for 1 hour at 1 mL/min.
Five column volumes PBS were used in washing (W fraction). The thrombin solution (1
mL) was then loaded onto the GSTrap column and incubated for 25 hours. Five column
volumes PBS were used to elute the cleaved Nipsnap1 (Cleavage, C fraction), then five
column volumes buffer A2 were used to elute GST (elution fraction, E).
A sample of the fractions were evaluated by Coomassie staining (Figure 28).
Thrombin incubation duration was also evaluated at additional timepoints (18 and 20 h)
and for Nipsnap1-NTF (not shown).
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Large-scale Nipsnap1 expression and purification
The verified Nipsnap1 pGEX-4T-1 plasmids were used to transform E. coli BL21
(DE3) cells (EMD Millipore). Cells were grown in LB media containing ampicillin at
37°C, with vigorous shaking. Nipsnap1 gene expression was induced using 0.1 mM IPTG
(Fisher) once an OD600=0.6 was reached, and cultures were spun down 3 h postinduction, and the resulting pellet was suspended in 80 mL PBS. Sonication (20%pwr, 1s
on/off, sit on ice 5 min, 3X) was performed and resulting lysate centrifuged for 1 h at
20,000xg/4°C. Supernatant was loaded onto the GSTrap FF column for 90 minutes,
washed with five column volumes of PBS, and then incubated with thrombin for 25 h at
room temperature. The GSTrap FF column was connected to the HiTrap benzamidine FF
column, and five column volumes buffer B1 used to elute cleaved protein. GST and
thrombin were eluted from their respective columns using buffers A2 and B2,
respectively. Coomassie staining (Figure 29) and Western blot analysis (Figure 30) were
used to verify Nipsnap1 purification and compare total protein yield with bacteria
transformed with control pGEX-4T1.
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III – RESULTS
CD spectroscopy indicates interaction with NAD+ causes a structural shift in
Nipsnap1
CD spectroscopy is a valuable technique for the analysis of protein features in
solution and can be used to observe conformational changes of a protein in the presence
of ligand (Kelly 2005). Near-UV CD data derived from Nipsnap1-FL purified in the pET28a purification system and NAD+ is shown in Figure 17. Marked changes in the
Nipsnap1 near-UV spectrum appear in the presence of NAD+ (i.e., development of the
large peak at 300 nm in the Nipsnap1-NAD+ spectrum), suggesting a shift in Nipsnap1
tertiary structure. Subtraction of the Nipsnap1 and NAD+ spectra from the Nipsnap1NAD+ spectra supports the hypothesis that NAD+ binding produces a structural change
in Nipsnap1 and is in agreement with previously derived data generated in biochemical
pulldowns of Nipsnap1 using NAD+ linked sepharose beads.
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Figure 17. Circular dichroism spectra for Nipsnap1, NAD+, and Nipsnap1 mixed with
NAD+. A difference spectrum was generated by subtracting the Nipsnap1 and NAD+
spectra from the Nipsnap1-NAD+ spectrum in the near-UV, indicating Nipsnap1
undergoes a structural change in the presence of NAD+.

Nipsnap1 expression does not affect growth of BL21(DE3)pLysS Cells
The observation that Nipsnap1 binds NAD+ suggests that Nipsnap1 may affect
NAD+ utilization and metabolism, thereby compromising bacterial growth. We
hypothesized that Nipsnap1 expression in E. coli results in a bacteriostatic effect, and that
NAD+ supplementation may improve bacterial growth. We tested this by generating
bacterial growth curves using the scheme in Figure 15. Both a physiologically relevant
and high concentration of NAD+ as reported previously were used in addition to
unsupplemented medium (Yongjin 2011).
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As shown in Figure 18A, bacterial growth was similar between cells transformed
with pGEX-4T1 Nipsnap1 compared to empty vector control. IPTG-induced cells had a
general reduction in growth rate. This is most likely attributed to induced cells having a
higher metabolic burden from increased protein synthesis following induction.
Additionally, the growth curves display a shift and plateau effect on log phase across all
induced samples. Uninduced cells appear to have increased bacterial growth during log
phase. Nipsnap1-expressing cells appeared to have slightly lower growth rates than
vector control samples. However, this difference did not appear to be significant.
As displayed in Figure 18B, no significant differences in growth curves for noninduced BL21(DE3)pLysS Competent Cells were detected, allowing conclusions to be
drawn if differences are observed between Nipsnap1 expressing cells and controls.
However, NAD+ supplementation at physiological concentrations (80 uM NAD+) shows
a significant difference in bacterial growth between Nipsnap1 inducing cells compared to
control. This effect is diminished when NAD+ is supplemented at a physiologically
extreme concentration (3 mM). The mechanism by which the differences in bacterial
growth in the presence of NAD+ between Nipsnap1 expressing cells and control manifest
is not known at this time.
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Figure 18. Bacterial growth curves generated pGEX-4T1 transformed cells (n=3). A) All growth
curves overlaid. cells transformed using pGEX-4T1 encoding Nipsnap1 are shown in solid lines,
and empty pGEX controls by dashed lines. pGEX denotes cells that were transformed using
empty pGEX-4T1 plasmid, pNS denotes cells transformed with Nipsnap1; number next to the
plasmid denotes condition. B) Nipsnap1-transformed cells versus control in each of the four
conditions. Condition 1 was not induced and had no NAD+ supplementation, condition 2 was
induced without supplementation. Conditions 3 and 4 are induced with low and high levels of
NAD+ supplementation, respectively.
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Initial parameters for Nipsnap1 induction and solubilization were not optimal
A Coomassie stain of SDS-PAGE separated bacterial proteins following an initial
solubilization procedure is shown in Figure 18. Nipsnap1-NTF (expected size ~43 kDa)
level was greatly reduced after centrifugation of the lysate to acquire the soluble fraction
that is loaded on the affinity column. Eluted fractions are not shown due to a lack of
protein. These results indicate that the vast majority of the induced Nipsnap1 protein
remained in the insoluble fraction. Therefore, a step-wise strategy to optimize the
expression, solubilization, and purification protocols to enhance protein yield was begun.
Conditions tested included bacterial culture time, temperature, broth composition, and
concentration of IPTG used in induction. Optimization of each of these conditions are
described in detail in the following sections.

Figure 18. Coomassie stain showing initial attempt at purification. NTF
Nipsnap1 was induced and grown at 37 °C for 6 h and lysed using initial
method. Column was incubated with thrombin for 4 hours. Wash and elution
fractions not shown due to showing no protein by Coomassie. NTF Nipsnap1
(43 kDa) protein is greatly reduced in soluble fraction compared to lysate.
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Optimization of Nipsnap1 induction
Duration of incubation time has little effect on total protein
First, length of time for bacterial growth post-IPTG induction for all three
Nipsnap1 constructs at 37°C (see Table 5 in methods) was compared to empty vector
GST control (Figure 20). In general, induction of Nipnsap1 proteins were at comparable
levels to GST control. Specifically, slightly lower induction was observed for Nipsnap1FL (57 kDa), whereas higher levels were observed Nipsnap1-NTF and Nipsnap1-CTF as
compared to GST control. In addition, 3h induction appeared to produce maximal protein
expression. However, a slight reduction in Nipsnap1-CTF (~40 kDa) was seen between 6
h to 3 h incubation periods. No differences were seen in Nipsnap1-NTF samples. In
conclusion, it appears that duration of incubation post-induction had little effect on total
protein across all samples.
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Figure 20. Coomassie stain of induced lysate samples and control. Ladder (L) is shown
for molecular weight comparison purposes. Reduction in induced protein was observed
between Nipsnap1-FL/CTF and control (+) samples. Induced bands are denoted with
arrows.

Post-induction incubation at 37 °C increased Nipsnap1 expression compared to 18 °C
Bacterial culture temperature post-induction was dropped from 37 °C to 18 °C in
an attempt to decrease the growth rate and reduce the chance that the expressed protein is
shuttled into insoluble inclusion bodies (Figure 21). Samples were taken at 6, 12, and 18
h post induction. Longer incubation times post-induction resulted in subtle increases in
Nipsnap1 expression, with less difference between 12-18 h time points compared to 6-12
h. Based on these results, 6 h post-induction time point was chosen for the subsequent
experiments.
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Manipulating IPTG concentration had little effect on total protein induction at 18 °C.
The use of IPTG to induce protein expression from plasmids can result in
pronounced physiological stress to E. coli (Dvorak 2015). Alterations in the
concentration of IPTG and the resulting effect on Nipsnap1-NTF induction was explored
by Coomassie staining (Figure 21). Coomassie staining indicated differences in IPTG
concentration had little effect on total protein production. Higher concentrations of IPTG
resulted in subtle increases in Nipsnap1 production.
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Figure 21. NTF Nipsnap1 expression in bacterial cultures induced with varying IPTG concentrations and grown for different
times visualized by Coomassie. Concentrations of IPTG and induction times are noted, and induced Nipsnap1-NTF is denoted
with arrow. Longer incubation times post-induction resulted in subtle increases in expressed Nipsnap1. The concentration of
IPTG has little effect on total protein induction.
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To determine if decreasing incubation temperature slows growth and increases
production of soluble Nipsnap1 protein, bacterial lysates and supernatants were compared
after induction at either 18 °C or 37 °C. Protein yield was determined by Coomassie
staining (Figure 22). There were no noticeable differences in overall induction levels
between the two protocols as detected by Coomassie staining, but Western blot analysis
indicated the 37 °C-based protocol resulted in higher levels of Nipsnap1-CTF protein.
Interestingly, the proportion of soluble Nipsnap1-CTF at the expected size (45 kDa)
compared to the lysate was higher using the 18 °C induction procedure, although the
overall level of induced protein in the lysate was lower than the 37 °C-based protocol.
This result suggests that lowering the incubation temperature may allow more protein to
be accessible for solubilization. An additional band can also be seen in immunoblot
analysis between 50-75 kDa. This may be attributed to dimerization/cross-linking of
Nipsnap1-CTF and a potentially truncated form of Nipsnap1. Alternatively, this may be
due to a post-translational modification of the Nipsnap1-CTF protein.
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Figure 22. Temperature effect on protein expression. CTF Nipsnap1 was
visualized by Coomassie staining (top two panels) or Western blot
analysis (bottom two panels), comparing protein yields after sonication
between 37 °C protocol 18 °C protocol or 37 °C protocol.

46

Optimization of Nipsnap1 solubilization
Lysozyme and NP40 addition did not increase the yield of soluble Nipsnap1
To increase the amount of protein in the soluble fraction, the addition of non-ionic
detergent NP40 and/or lysozyme, a hydrolase that can compromise bacterial cell wall
integrity, was examined for impact on Nipsnap1 recovery from the soluble fraction
(Figure 23). Overall, no difference was observed in total soluble protein between the
three conditions.
The strain of E. coli used in this study (BL21(DE3)pLysS) has been genetically
engineered to express lysozyme, in order to help degrade cells walls after lysis has been
initiated. Therefore, it was expected that supplementation of additional lysozyme would
have no additional effect. NP40 is a non-ionic detergent often used to lyse membranes.
Addition of NP40 may not be useful simply due to the harsh nature of sonication. In
addition, NP40 does not seem to solubilize proteins that may be located in inclusion
bodies.
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Figure 23. Coomassie stain comparing solubilization procedures using
lysozyme or NP40. Pellets generated during lysate centrifugation were
resuspended in either PBS with 1% NP40, lysozyme, or both. Generated
solutions of PBS and pellet were incubated and again sonicated, aliquots
were taken for analysis, then samples were again centrifuged, with the
supernatants saved to be visualized by Coomassie. This was performed for
all three conditions (NP40 addition, lysozyme addition, and addition of
both).
Less stringent sonication conditions increased yield of soluble protein
Evidence suggests that prolonged sonication of bacterial cells may cause protein
aggregation and fragmentation, resulting in the localization of expressed protein into
‘”apparent” inclusion bodies (Stathopulos 2004; Williams 1982). To address this issue, a
less stringent sonication protocol was compared to the initial procedure (Table 6 in
Methods), and samples were visualized by Western blot analysis (Figure 24). Western
blot analysis demonstrates that a greater proportion of expressed Nipsnap1 was found in
the soluble fraction using the milder sonication method in comparison to the proportion
found in the soluble fraction using the initial sonication method. Western blot analysis
also indicated that two forms of Nipsnap1 are being expressed, a faint band just above 37
kDa (expected size for Nipsnap1-CTF is 45 kDa) and an intense band just above 25 kDa.
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The band at the desired size shows a reduction in Nipsnap1 intensity after collection of
the soluble fraction. It is important to note that the pET-28a CTF Nipsnap1 does not
contain the entire epitope sequence recognized by the used αNS1 antibody, and therefore
cannot be visualized.
The predominant band at ~25 kDa is likely to be a truncated form of GSTNipsnap1 that corresponds to the entire GST protein (26 kDa) and the initial segment of
Nipsnap1-CTF containing the epitope sequence. This lack of complete protein translation
could be the result of non-optimized codon usage in the plasmid, which encodes the
mouse Nipsnap1 cDNA.

Figure 24. Comparison of Nipsnap1-CTF solubilization using initial and
final sonication methods. A greater proportion of expressed Nipsnap1 is
found in the soluble fraction for the milder sonication method in
comparison to the proportion found in the soluble fraction using the initial
sonication method. Initial and final Western blots were run separately.
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Large-scale expression with optimized lysis and purification results in truncated
Nipsnap1 proteins
To increase total protein yield, cultures transformed with pGEX4T1 containing
Nipsnap1-CTF were scaled up to 1-liter and grown using the 37 °C based induction
protocol and the modified sonication procedure (see methods). Protein levels were
determined by Coomassie staining (Figure 25) and Western blot analysis (Figure 26). In
general, much lower levels of Nipsnap1-CTF protein were induced than GST control
when visualized by Coomassie staining (Figure 25 & 26, left panels). Cells that express
Nipsnap1-CTF displayed a reduction in all bacterial proteins.
The expected size for the GST-CTF Nipsnap1 is 40 kDa. However, both
Coomassie staining and Western blotting show multiple bands at different sizes. The
predominant form of Nipnspa1-CTF is approximately 30 kDa, with much lower amounts
of the higher molecular weight forms (~40 kDa and ~55 kDa). These results suggest that
Nipsnap1-CTF is not being fully translated during induction. This could be due to nonoptimized codon usage in the plasmid, since the construct contained mouse Nipsnap1
cDNA sequence. Higher amounts of full-length Nipsnap1-CTF may be obtained by using
a modified cDNA which contains optimized E. coli codons.
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Figure 25. Coomassie staining of samples from purification of supernatants generated from cultures transformed with empty pGEX4T1 or Nipsnap1-CTF in pGEX-4T1. Wash fractions expected to remove nonspecifically bound proteins are denoted (Wn). Elution
fractions after thrombin incubation to promote cleavage of GST-Nipsnap1 are denoted (Cn). Elution fractions after addition of reduced
glutathione to the GSTrap column are denoted (Gn). Elution fractions after addition of buffer B2 to remove thrombin from HiTrap
column are denoted (En). The solid arrow, solid line, and dashed arrow correspond to approximate locations for GST-Nipsnap1,
cleaved GST, and cleaved Nipsnap1, respectively.
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Figure 26. Western blot analysis of samples from purification of supernatants generated from cultures transformed with pGEX-4T1
encoding CTF Nipsnap1. Wash fractions expected to remove nonspecifically bound proteins are denoted (Wn). Fractions expected to
elute cleaved protein are denoted (Cn). Fractions expected to remove GST from GSTrap column are denoted (GEn). Fractions
expected to remove thrombin from HiTrap column are denoted (Hn). Solid and dashed arrows correspond to expected locations of
GST-Nipsnap1 and cleaved Nipsnap1, respectively.
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Coomassie staining and Western blot analysis also indicate that cleavage of GSTNipnsnap1 by thrombin is not occurring efficiently. Thrombin incubation was performed
at a range of incubation durations, with trials using fresh thrombin aliquots from multiple
shipments (not shown). These results may be due to an inaccessible cleavage site due to
the structural conformation of Nipnsap1 protein.
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IV - DISCUSSION
The major focus of my study was to optimize conditions for maximal production
and purification of recombinant Nipsnap1 proteins. A variety of conditions were
evaluated, including culture media composition, induction temperature and time, lysis
buffer formulations, sonication procedures, and thrombin digestion time. Even with
optimized induction and purification conditions, the expression of Nipsnap1-FL,
Nipsnap1-NTF and Nipsnap1-CTF GST fusion proteins were low compared to the GST
control.
The low expression of Nipsnap1 protein does not appear to be caused by a
bacteriostatic effect (toxicity) of Nipsnap1 or to instability of Nipsnap1 protein. Using
growth curve analysis, bacterial growth rates were found to be similar when expressing
GST control compared to GST-Nipsnap1 fusion protein. However, expression of GST or
GST-Nipsnap1 fusion protein did lower bacterial growth rate compared to uninduced
controls. To address the instability issue, a GST fusion expression system was used,
whereby Nipsnap1 coding regions were fused in-frame with GST. However, the levels of
GST fused Nipsnap1 proteins were still quite low.
Although GST fusion proteins can stabilize some proteins (Kaplan 1997), GST
has been demonstrated to be a poor fusion partner for solubility when compared to other
common fusion partners, resulting in increased compartmentalization of target protein
into inclusion bodies (Hammarström 2002; Hammarström 2006; Dyson 2004; Kohl 2008;
Ohana 2009). Due to troubles in solubility with usage of the GST-fusion strategy, other
fusion partners that result in higher solubility while maintaining protein stability when
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compared to GST may be desirable as a fusion partner for future Nipsnap1 expression
and purification efforts. A wide variety of fusion proteins exists for heterologous protein
expression in E. coli that increase solubility and aid in protein purification (Costa 2014).
Newer fusion systems such as the SUMO (Butt 2005), Halo (Ohana 2009), SNUT
(Caswell 2010), expressivity tag (Hansted 2011), or Fh8 (Costa 2013) may yield greater
amounts of stable, soluble Nipsnap1 for use in a variety of downstream assays to study its
biochemical function.
In order to increase the yield of purified Nipsnap1 proteins, large-scale
experiments were performed. The majority of purified Nipsnap1 existed in truncated
forms. This is likely due to different codon usage in mammalian cDNAs compared to
bacteria, which is known to decrease heterologous protein expression in E. coli
(Gustafsson 2004; Rosano 2009). Optimization of the codons to better accommodate
those preferred by E. coli (Sharp 1988) may lead to a substantial increase in heterologous
protein expression. Additionally, certain E. coli cell lines exist that are engineered to
contain additional copies of genes that code for tRNAs that reduce expression of
heterologous proteins, including BL21-CodonPlus (Agilent Technologies), allowing
higher-level expression of genes that are expressed poorly in conventional BL21 strains.
Figure 27 shows the mouse Nipsnap1 cDNA sequence used to generate fulllength Nipsnap1 and the corresponding primary amino acid sequence. We found 31
codons out of a total of 284 (11%) that may cause translational problems in E. coli as
reported in literature (Chen 2006). Notably, 19 out of the 31 (61%) problematic codons
were enriched in the C-terminal portion of Nipsnap1. A premature truncation at position
560, where two consecutive unoptimized codons are found, would result in a GST55

Nipsnap1-C truncation protein with a hypothetical molecular weight of roughly 31 kDa,
consistent with the primary form of expressed Nipsnap1found during purification (Figure
26). If codon optimization is pursued in future work, the highlighted sequences of
Nipsnap1 cDNA found in Figure 27 would likely give the most benefit to heterologous
Nipsnap1 expression when altered.
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Figure 27. Nipsnap1 cDNA sequence used to generate full-length Nipsnap1. Codons that may cause translational problems due to
insufficient tRNA in E. coli are highlighted. A significant number (61%) of potentially problematic codons are found within the Cterminus of Nipsnap1. These areas would likely contribute the greatest benefit to successful overexpression if mutagenesis was
performed to accommodate more common codon usage in E. coli.
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Initial CD spectroscopy experimentation demonstrated that Nipsnap-FL can
directly bind to NAD+ (Figure 17). CD spectroscopy is a valuable technique for the
analysis of protein features in solution and can be used to observe conformational
changes of a protein in the presence of ligand (Kelly 2005). Measurements can be carried
out rapidly (<30 min) and conveniently. Protein crystallization is not required for
analysis, and generally samples utilized in CD experimentation can be recovered and
used in further assays due to the methods non-destructive nature. However, there are
several limitations to CD spectroscopy (Kelly 2000). CD provides low resolution
structural information, and by itself fails to give detailed information about a protein’s
tertiary or quaternary structure. Tertiary information is found in the near UV (350-250
nm) spectral region, where signals of interest are primarily produced by the
chromophores found in aromatic amino acid side chains (320-260 nm) and disulfide
bonds (weak, broad absorption bands around 260 nm). Proteins lacking sufficient
amounts of amino acids with the above chromophores will fare poorly in CD
experimentation.
Isothermal calorimetry (ITC) is a technique that may result in a more definitive
validation of Nipsnap1-NAD+ binding. ITC is a powerful technique that can resolve the
enthalpic and entropic components of binding affinity (Leavitt 2001). ITC can
additionally be used a tool to validate computational structure-based predictions of
binding energetics, and allow for accurate structure/energy correlations. Analysis of the
Nipsnap1-NAD+ interaction by ITC would allow direct measurement of the energy
associated with NAD+ binding to Nipsnap1. A high concentration of purified Nipsnap1
would be desired for ITC experimentation.
58

Taken together, my results support the hypothesis that Nipsnap1 interacts with
NAD+ because CD spectroscopy revealed a tertiary protein structure change in Nipsnap1
when NAD+ was present. However, additional experiment and additional controls are
needed to determine the binding affinity of NAD+ (and NADP+) to Nipsnap1. Although
several different procedures were tested for optimization of Nipsnap1 expression, none
were effective at producing large amounts of recombinant Nipsnap1 protein. I also
demonstrated that Nipsnap1 overexpression did not cause a bacteriostatic effect in
bacteria. A method for overexpression and purification of large amounts of Nipsnap1
protein has yet to be developed. Future work pursuing this goal using a bacterial
expression system should focus on using an E. coli optimized Nipsnap1 cDNA construct
and the modified induction and solubilization methods developed in this study. Such a
system would be invaluable in elucidating Nipsnap1 function, allowing evaluation of
protein structure and function in a number of assays that rely on high quantities of
purified protein.
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APPENDIX

Figure A1. Coomassie stain of the pET-28a-based recombinant Nipsnap1 purification
strategy (Gacasan, unpublished). The His-tagged Nipsnap1 protein (30kDa) was purified
using Ni-Affinity chromatography. Supernatant was cycled onto a 1 mL Ni sepharose
HisTrap HP column (GE Health Sciences) for 1-2 hours at 40 °C, using a peristaltic
pump, to ensure maximum protein binding. The column was then washed with buffer A
for 20 min, to remove any nonspecifically bound protein, and the bound protein eluted
with buffer B (20mM NaPO4, 0.5M NaCl, and 500mM imidazole, pH 7.4).
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Figure A2. Immunoblot analysis pET28-a recombinant Nipsnap1 protein. Truncated
recombinant Nipsnap1 forms were probed with an αHis6 antibody as opposed to our
generated αNS1 antibody due to not containing the complete antibody epitope sequence
(Epitope = NKLKNNKEYLEFRKER). A) Full-length recombinant Nipsnap1 (30 kDa)
was probed with 1:4000 αNS1 generated in our lab and 1:5000 αgoat. Of interest to note
is the dual banding of purified recombinant protein. B) N-terminal fragment recombinant
Nipsnap1 was probed with 1:1000 αHis6 antibody and 1:5000 αmouse, showing no
observed expression. C) C-terminal fragment recombinant Nipsnap1 was probed
with1:1000 αHis6 antibody and 1:5000 αmouse. No significant expression is observed.
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